CRISPR and Cancer

In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...

A Danish start-up, BioPhenyx, has developed a functional genetic assay that uses CRISPR to evaluate the effects of any mutation of interest. The...

In this week's clinical update, we look at recent news from Caribou Biosciences. The company's second gene-edited CAR-T cell therapy candidate,...

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

In this update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer...

This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Last week, Allogene Therapeutics announced the publication of data from the Phase 1 UNIVERSAL trial of ALLO-715, a TALEN-engineered CAR-T candidate...